reason report
progress solid symdeko launch tripl phase fda
bottom line vertex report solid result
market close yesterday revenu beat consensu
also disclos initi second cystic fibrosi cf tripl
combin phase compani experienc
now-rar stumbl believ stori valu proposit
intact peer compani multipl contract
reduc target price vertex short valuat
believ stock offer attract growth profil modest
develop competit risk
deuterated-kalydeco initi tripl phase iii last night
vertex disclos second phase tripl combin would
includ deuter version ivacaftor previous licens
concert vx fda determin product would
requir full develop novel nce delay time
develop associ combin least year result
vertex revert plan consist instead advanc
second similar tez/iva base tripl combin contain
virtual ident phase trial mean compani
run two roughli equival hors expens race
risk mitig strategi laudabl seem
expens term trial cost time revenu foregon
necessari vertex may still develop contain once-daili
tripl combin product might come market
fda stanc provid reassur
vertex competit posit fda clearli signal
short-cut least us tradit good drug develop
practic indic vertex single-tablet combin
pill current phase combin also requir
singl kalydeco tablet even well
first tripl sale like previous assum
door open late tripl launch us
seem unlik given updat develop plan
assum first quarter sale tripl
chang particularli meaning forecast sinc vertex
primari competitor galapago seem closer us pivot trial
six month ago galapago small combin trial could
demonstr proof concept viabl tripl program could still
lead dose rang develop pivot trial
average ep rev
disc dcf wacc
tg
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
updat model includ delay tripl measur
symdeko result perform increment disclosur
time reduc revenu forecast
left later year forecast larg unchang
continu forecast rapid revenu growth vertex almost
global sale revenu forecast
remain significantli consensu year beyond
continu expect signific increas expens
balanc year although long term expect vertex ebit margin
exceed tax rate forecast reduc base manag
updat comment result pro forma ep estim
increas later year adjust
ep estim materi higher consensu
period base updat revenu earn estim
chang peer compani multipl recent month
lower target price vertex reiter
outperform rate vertex remain one uncompl growth
stori larg cap biotech expect recov recent
weak toward target price come month
price target vertex rate stock outperform thesi base
expect continu captur cystic fibrosi cf patient subpopul vertex
success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio consid competitor forecast
valuat believ develop path time market challeng vertex
well posit partner acquir show promis flirt profit
past vertex seem determin maintain recent recov profit appear
capabl grow oper margin end
beyond compani still aspir discov develop drug categori larg
diversifi invest associ expens risk thesi valuat howev
potenti sizabl near-term growth stock offer strong valuat upsid potenti
next month
revenu grew qoq yoy beat consensu
orkambi sale fell short consensu newly-launch symdeko sold
beat consensu fell short consensu estim
kalydeco revenu also beat consensu also beat estim
total cf revenu consensu forecast vertex
gross margin line expect better consensu
discretionari expens sg estim
consensu result non-gaap ep estim
consensu due larg non-oper tax item vertex maintain
compani previou guidanc total cf revenu non-
 sg
import driver vertex stock develop potenti commerci
tripl combin last quarter vertex announc initi two tripl combin trial
use one heterozyg cf studi one homozyg cf
week studi see note tripl pivot trial short sweet launch
feasibl conjunct yesterday earn call vertex unveil plan second
tripl combin phase trial compar phase ii produc
slightli higher increas absolut percent predict forc expiratori volum one
second baselin homozyg vs heterozyg vs
cf patient therapeut dose trial mimic design short
durat previously-announc trial similarli enrol approxim
heterozyg patient homozyg patient trial like approxim
month behind studi requir week follow safeti file
although primari endpoint efficaci week respons
vertex purchas concert potenti replac kalydeco
compon futur tripl combin would reduc pill burden twice-a-day
once-daili see note kalydeco challeng intern asset vertex
yesterday announc first patient result molecul tripl combin vx-
heterozyg cf patient produc mean
absolut improv baselin week result
look almost ident would expect result similar combin contain
ivacaftor once-daili triple-combin regimen describ gener well toler
safeti result consist kalydeco trial howev vertex hope
move asset next tripl combin regimen phase announc
advis fda requir full develop includ
human safeti dose rang monotherapi begin tripl combin pivot
yesterday vertex disclos second phase tripl combin would includ vx-
delay time develop contain combin least
year treat molecul new nce compani oblig complet independ
human safeti dose rang pk/pd studi mean product realist
month readi tripl combin phase trial
result decis agenc vertex revert plan consist
advanc second similar tez/iva base tripl combin contain
virtual ident phase trial mean compani run two roughli
equival hors expens race obviou risk mitig
strategi laudabl seem bit expens term trial cost revenu
foregon necessari suspect compani anticip agenc
respons might approach earlier develop decis make slightli
differ instead tripl immedi file end phase tripl
one pill/day conveni later file product compani plan make
choic two pre-fil mean tripl contain delay
term file timelin least tripl complet pivot trial compani
decid best profil shelv vertex may still develop
contain once-daili tripl combin product might come market
fda stanc provid reassur vertex competit posit fda
clearli signal short-cut least us tradit good drug
develop practic indic compound close kalydeco requir
independ develop dose rang safeti pk/pd test everi
novel cf corrector potenti come market vertex single-tablet
combin pill current phase combin also requir singl
kalydeco tablet even well
previous assum door open late tripl launch us
seem unlik given updat develop plan assum first
quarter sale tripl
non-cf pipelin program continu emerg vertex plan begin phase
i/ii studi two indic gene edit candid partner crispr
therapeut incorpor crispr technolog initi
studi pair phase i/ii trial beta-thalassemia sickl cell diseas vertex
yet provid detail regard design trial
current assign valuat either program model
vertex also expect report result phase ii studi neuropath pain select
updat model includ delay tripl measur symdeko follow
quarter result made slight chang revenu forecast margin assumpt
ep estim go forward revenu forecast decreas
less unchang later year line recent
consensu higher higher later
year gross margin remain high rang oper margin increas
year almost tax rate forecast
reduc substanti base manag comment short term outlook
longer term believ compani opportun keep tax rate high teen
rather previous forecast forecast pro-forma dilut ep
increas later year ep estim remain
significantli consensu higher later year although
ep estim margin higher multipl compar compani declin
significantli last month result chang model compress
peer compani multipl reduc price target maintain
outperform rate vertex stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim
discount back year compani cost equiti give valu one year
use averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim post-tripl
discount back year compani cost equiti give valu one
year lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price
target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time result
cf children year old
cf children age month
cf age
eu approv
het min cf cf
het min cf cf
late stage pipelin program includ
late stage pipelin program exclud
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
leerink partner research compani file
million
product sale direct product sale vertex
sale
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method large-cap healthcar ep multipl lp normal earn
current averag growth larg cap biopharma multipl ep nvo azn
leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
leerink partner research compani file factset
